EDAS Revascularization for Symptomatic Intracranial Atherosclerotic Disease (Phase IIb)
Official title: ERSIAS Phase IIb EDAS Revascularization for Symptomatic Intracranial Atherosclerotic Steno occlusive Disease Phase IIb Clinical Trial
Funded at Cedars-Sinai Medical Center · NIH-11439959 · Data updated 2026-11-12
A multicenter phase IIb clinical trial tests a surgical bypass option called EDAS to reduce stroke risk in people with symptomatic intracranial atherosclerotic disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 23, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $2,622,192 |
| NIH project number | 1UG3NS150909-01 |
| Project ID | NIH-11439959 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with symptomatic intracranial atherosclerotic disease who meet trial criteria and are eligible for the EDAS procedure.
✕Less likely to help
Some participants may not benefit and could experience procedure-related risks or no improvement in stroke risk.
What this research studies
If you have a history of stroke symptoms due to narrowing of the brain arteries, this study tests EDAS, a surgical bypass approach, against standard medical care. Participants are enrolled across multiple centers and randomly assigned to the EDAS procedure or current medical management, with careful monitoring for safety and stroke outcomes. The goal is to see if EDAS can improve blood flow to the brain with manageable risk compared to routine treatment. This phase IIb trial builds on prior research suggesting EDAS may offer benefit with lower perioperative risk.
Why it matters
Potential benefit: If successful, EDAS could become a safer surgical option to reduce stroke risk for people with ICAD.
How similar studies have gone: Previous trials with other procedures had mixed results, but EDAS has shown promise in reducing perioperative risk and improving perfusion in related conditions.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Gonzalez, Nestor Raul — Cedars-Sinai Medical Center
- Study coordinator: Gonzalez, Nestor Raul
Related research
Other NIH-funded projects on the same topics.
-
Lipid signals that control acetyl-CoA and fat metabolism in NAFLD
A study exploring how membrane lipids influence acetyl-CoA metabolism to understand and potentially treat nonalcoholic fatty liver disease (NAFLD).
-
Them1’s role in fat metabolism and MASLD progression
Aims to understand how a fat-regulating protein (Them1) affects energy use in fat and liver, and how this could contribute to MASLD in people who are overweight.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Alpha5 integrin's role in ALS: how a cell switch worsens disease
Aims to understand how a specific protein called alpha5 integrin in immune cells affects ALS progression and whether blocking it can help extend life.
-
Chlamydia pneumoniae infection and Alzheimer's disease progression
This project looks at whether a common lung infection, Chlamydia pneumoniae, might influence Alzheimer's disease in people and what that could mean for treatment.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.